These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9257738)

  • 1. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.
    Zix JA; Geerdes-Fenge HF; Rau M; Vöckler J; Borner K; Koeppe P; Lode H
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1668-72. PubMed ID: 9257738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.
    Kamberi M; Nakashima H; Ogawa K; Oda N; Nakano S
    Br J Clin Pharmacol; 2000 Feb; 49(2):98-103. PubMed ID: 10671902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.
    Lee LJ; Hafkin B; Lee ID; Hoh J; Dix R
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2196-200. PubMed ID: 9333047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.
    Stass H; Schühly U; Möller JG; Delesen H
    Clin Pharmacokinet; 2001; 40 Suppl 1():49-55. PubMed ID: 11352442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization.
    Kamberi M; Kotegawa T; Tsutsumi K; Nakamura K; Nakano S
    Eur J Clin Pharmacol; 1998 Oct; 54(8):633-7. PubMed ID: 9860151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction of sparfloxacin and digoxin.
    Johnson RD; Dorr MB; Hunt TL; Conway S; Talbot GH
    Clin Ther; 1999 Feb; 21(2):368-79. PubMed ID: 10211539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Maalox on the oral absorption of sparfloxacin.
    Johnson RD; Dorr MB; Talbot GH; Caille G
    Clin Ther; 1998; 20(6):1149-58. PubMed ID: 9916608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of products containing metal ions on the absorption of lomefloxacin.
    Lehto P; Kivistö KT
    Clin Pharmacol Ther; 1994 Nov; 56(5):477-82. PubMed ID: 7955811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cimetidine does not alter sparfloxacin pharmacokinetics.
    Gries JM; Honorato J; Taburet AM; Alvarez MP; Sadaba B; Azanza JR; Singlas E
    Int J Clin Pharmacol Ther; 1995 Nov; 33(11):585-7. PubMed ID: 8688981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.
    Pletz MW; Preechachatchaval V; Bulitta J; Allewelt M; Burkhardt O; Lode H
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1129-31. PubMed ID: 12604553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg.
    Montay G; Bruno R; Vergniol JC; Ebmeier M; Le Roux Y; Guimart C; Frydman A; Chassard D; Thebault JJ
    J Clin Pharmacol; 1994 Nov; 34(11):1071-6. PubMed ID: 7876398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of sparfloxacin.
    Shimada J; Nogita T; Ishibashi Y
    Clin Pharmacokinet; 1993 Nov; 25(5):358-69. PubMed ID: 8287631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antacid medication on the pharmacokinetics of temafloxacin.
    Granneman GR; Stephan U; Birner B; Sörgel F; Mukherjee D
    Clin Pharmacokinet; 1992; 22 Suppl 1():83-9. PubMed ID: 1319875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review.
    Montay G
    J Antimicrob Chemother; 1996 May; 37 Suppl A():27-39. PubMed ID: 8737123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers.
    Allen A; Bygate E; Faessel H; Isaac L; Lewis A
    Int J Antimicrob Agents; 2000 Aug; 15(4):283-9. PubMed ID: 10929878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.
    Wise R; Jones S; Das I; Andrews JM
    Antimicrob Agents Chemother; 1998 Feb; 42(2):428-30. PubMed ID: 9527799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval).
    Morganroth J; Talbot GH; Dorr MB; Johnson RD; Geary W; Magner D
    Clin Ther; 1999 May; 21(5):818-28. PubMed ID: 10397377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of enrofloxacin in lactating sheep.
    Haritova A; Lashev L; Pashov D
    Res Vet Sci; 2003 Jun; 74(3):241-5. PubMed ID: 12726743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fenbufen on the pharmacokinetics of sparfloxacin in rats.
    Naora K; Katagiri Y; Iwamoto K; Tanaka K; Yamaguchi T; Sekine Y
    J Antimicrob Chemother; 1992 Nov; 30(5):673-83. PubMed ID: 1337351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.
    Ritz M; Lode H; Fassbender M; Borner K; Koeppe P; Nord CE
    Antimicrob Agents Chemother; 1994 Mar; 38(3):455-9. PubMed ID: 8203837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.